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This thesis expands prior work with DNA aptamers to investigate the nature of 
target molecule binding and hybridization of a set of preselected aptamers for vascular 
endothelial growth factor (VEGF). This work is motivated by the need for better 
understanding of the interplay between hybridization activity and non-nucleotide target 
molecule binding to aptamers in order to optimize aptamer-functionalized colloidal 
therapeutics and diagnostic tools using aptamers. Previous work established that it was 
possible to induce release of bound VEGF from aptamers using primary hybridization of 
complementary DNA as a release trigger. These studies expand on this concept by 
utilizing secondary hybridization events to then release the primary DNA target to 
recycle or regenerate the aptamer for subsequent binding and release events with either 
VEGF or with DNA targets. This body of work explores methods to maximize primary 
and secondary hybridization efficiency and aptamer binding while minimizing 
understandable nonspecific interactions with the aptamer-functionalized colloidal 
particles. Chapter 1 provides an overview of colloidal particles, DNA and its properties, 
aptamers, VEGF, and previous applications of aptamers in therapeutic schemes. Chapter 
2 discusses the selection of the DNA aptamers and sequences of interest and details the 
steps taken to optimize primary hybridization of aptamer functionalized microspheres. 
Chapter 3 focuses on controlling the binding of VEGF to the aptamer functionalized 
colloidal particles. Chapter 4 analyzes the nature of competitive binding and 
displacement of both complementary DNA and VEGF. Chapter 5 discusses the 







 The use of deoxyribonucleic aptamers has become more prevalent over the last 
decade. Aptamers are oligonucleotides with high specificity and affinity to non-
nucleotide targets ranging from molecules such as theophyline to macromolecules such 
as cell proteins.
[1]
 The interest in deoxyribonucleic acid (DNA) aptamers stems from its 
unique properties as ligands and ability to modify the DNA macromolecule. Specifically 
the ability to select, synthesize, and immobilize DNA aptamers to material surfaces has 
the potential to surpass the decades older process of using antibodies, cutting down the 
time required to identify, design, and implement therapeutics solutions. Additionally, 
tailoring the complementarity, melting temperature, and length of the DNA sequences 
allows for controlled interactions between the aptamer ligand, its non-nucleotide target 
molecule, and one or more nucleotide target (e.g. DNA, RNA) to design delivery vehicles 
with programmable release of therapeutics as well as recyclable or regenerative binding 
capabilities. Polymer microspheres have been used as a substrate for immobilized DNA 
for the purpose of serving as a model therapeutic delivery vehicle.
[2-4]
This literature 
review will outline the fundamentals of colloidal interactions of these polymer 
microparticles as well as, the role of DNA as a biological macromolecule, aptamer-non-
nucleotide target interactions and aptamer selection, and highlight the relevance of 





1.1 Colloidal Particles: Interactions and Aggregation 
1.1.1 - Colloidal Particles and Size Regimes 
 At the colloidal size regime surface-based interactions dominate in determining 
the behavior of the colloidal systems, meaning that factors such as the presence of 
charged functional groups, adsorbed molecules, and solution conditions such as pH, ionic 
strength, and temperature play a significant role in determining the behavior of 
suspensions.
[5]
 Typically, particles possessing a single dimension between 10
-3
 and 1 µm 
fit this description, but some particle dimensions can exist outside of this range.
[6-8] 
Various shapes and compositions are available in colloidal species, but surface 
composition often dominates in determining the observed behavior in a colloidal 
suspension. As a result colloidal suspensions can display a wide variety of phase behavior 
ranging from fluid like systems of repulsive particles at a dilute concentration to more 
highly concentrated gels formed from attractive particles.
[9]
  Fluorescence microscopy, 
confocal microscopy, flow cytometry, and spectroscopy are some of the multitude of 
tools available for the characterization of colloidal suspensions, allowing researchers to 
analyze the structure within the suspensions or investigate surface functionalities found 
on the particle surfaces.
[10]
 Nonspecific interactions such as repulsive electrostatic, 
attractive van der Waals, and repulsive steric interactions are commonly used to control 
colloidal interactions and the resulting phase behavior.
[9]
 The classic Derjaguin, Landau, 
Verwey, and Overbeek (DLVO) theory is commonly used to predict colloidal stability of 
homogeneous suspensions in polar mediums and accounts for electrostatic and van der 
Waals interactions.
[11]
 Figure 1.1.1 is a representative schematic of DVLO interaction 




Figure 1.1.1: Schematic representation of the distant-dependent DLVO potential energy 
curves for a pair of identical particles. a) A deep primary attractive well that results in 
irreversibly aggregated particles, b) a secondary attractive well, causing weaker 
reversible attraction between particles at a larger separation distance, and c) a completely 
repulsive interaction potential, yielding stable disperse particles. W is a stability ratio 
which favors aggregation when less than 1.
[5]
 
 While stable suspensions of repulsive identical particles, such a repulsion based 
approach is typically insufficient to direct the arrangement of neighboring particles, 
particularly in heterogeneous suspensions comprised of different repulsive particles. To 
further augment the degree of control over the phase behavior, colloidal surfaces can be 
functionalized with desirable biomacromolecules capable of mediating specific 
interactions. In addition to the specific attractive interactions, it should be noted that the 
polymeric nature of these biomacromolecules can also be used to further stabilize 
colloidal suspensions through the introduction of entropic effects to steric repulsion 
interactions. The repulsion creates a system unfavorable to nonspecific aggregation by 
overcoming attractive van der Waals interactions across small distances. Furthermore, 
these surface-bound biomacromolecules typically possess charge groups.  Thus, while 
these electrostatic effects can mask nonspecific attractive interactions, one typically must 
add sufficient counter ion species in order to allow for match biomacromolecules such as 




employing specific interactions to mediate colloidal interactions can be found in the early 
work of Mirkin et al.
[16] 
and Alivisatos et al.
[17]
 have previous published reports on DNA-
based nanoparticle assembly. Their work utilized gold nanoparticles (Au NPs) and 
immobilized thiolated DNA to bridge surfaces together using DNA hybridization events, 
allowing them to design complex colloidal aggregates. In separate work by Pena’s group, 
enzymatic extension of the immobilized DNA template
[18]
 and the incorporation of 
complementary spacer DNA strands has allowed for the incorporation of long DNA 
strands on particles and brought new levels of diversity to the design of colloidal 
vehicles.  
 
1.2 - Deoxyribonucleic Acid as a Biological Macromolecule 
 
1.2.1 - Deoxyribonucleic Acid and its Properties  
 Oligonucleotides are biological polymers composed from repeating nucleotide 
units.
[19] 
Nucleotides consist of alternating five carbon deoxyribose sugar group and 
negatively charged phosphate to form the deoxyribonucleic backbone. Additionally, one 
of four following nitrogenous bases are attached as a side group: adenine (A), guanine 
(G), cytosine (C), or thymine (T). These bases interact with one another through 
hydrogen bond formation during the formation of a deoxyribonucleic acid (DNA) duplex. 
Below a schematic of the four bases and the specific Watson-Crick base interactions 
between purines (G, A) and pyrimidines (C, T) is shown in Figure 1.2.1 in which adenine 








Figure 1.2.1: Hydrogen bonding according to Watson-Crick base pair interactions, 
showing the characteristic three hydrogen bonds between guanine (G) and cytosine (C) 







Figure 1.2.2:  Schematic illustration of DNA duplex comprised of two complementary 
sequences that hybridize to form an anti-parallel helix in which the central core is 
comprised of hydrophobic bases while the periphery of the duplex is comprised of the 
hydrophilic sugar-phosphate backbone. Adapted from 
http://www.accessexcellence.org/RC/VL/GG/dna2.php, accessed 11/7/2104) 
 
 As illustrated in Figure 1.2.2, the classical double helical structure of DNA is then 





stacking contributions from the pi bonds found with the bases. This regular structure and 
the redundancy of the complementary strands makes DNA an excellent choice for the 
storage of genetic information. Compared to RNA, the deoxygenated sugar group of 
DNA offers greater resistance to nuclease degradation in vivo, and it has base specificity 
that serves as a critical factor in DNA replication and the transcription of DNA to RNA 
for protein synthesis allowing for high fidelity throughout generations of cells.  
 
1.2.2 Biological Function of DNA 
 DNA is a central molecule in the function of all cellular processes. It serves as a 
coding source for the genetic material of all organisms and acts as a director of the 
systems in charge of replication, transcription of RNA and ultimately protein synthesis, 
and silencing of cellular functions.
[21]
 DNA is tightly packed in the nucleus of eukaryotic 
cells in nucleosomes, long sequences of methylated DNA wrapped around histones. 
Specific base pairing between the four nucleotides according to Watson-Crick base 
pairing serves as the basis of the genetic code, ensuring consistency in the genome during 
protein synthesis and cellular proliferation. With every three nucleotides coding for a 
different amino acid during transcription, DNA is responsible for the formation of all the 
proteins within an organism with alternative slicing pathways to ensure that the limited 
diversity of the four base DNA alphabet allows for the generation of diverse proteins.  
1.2.3 DNA Aptamer structure, function, selection, and clinical relevance 
 Aptamers, for the purposes of this thesis, are defined as oligonucleotides capable 
of specifically binding to a non-oligonucleotide target molecule. These can range from 
small molecule targets like ampicillin
[22]





 Aptamers can be derived from ribonucleic acid (RNA) or peptides as well, but DNA 
aptamers have been gaining notoriety due to the increased nuclease resistance they offer 
over more traditional RNA systems. Additional attributes include the ease with which 
they can be altered before and after synthesis to further optimize binding affinity or attach 
functional groups for various applications. They are also being explored as alternates to 
more commonly used multivalent ligands such as antibodies for similar reasons. While 
antibodies have to be extracted from animal fluids following antigen injection, DNA 
aptamers can be handled and derived inside a test tube through processes involving 
sequences that are a few dozen to a few hundred nucleotides in length.
[24]
 Aptamers have 
the potential to fill a similar role as antibodies in clinical use by serving as a targeting 
agent to relevant biological markers (e.g. cell receptros) in vivo or as diagnostic tools 
capable of verifying the presence of known pathogens or markers associated with specific 
diseases.
[25] 
 With the increase in interest in oligonucleotides as bio-inspired ligand alternatives 
to antibodies, it has become important to understand the role of aptamer structure in 
specific aptamer-target binding interactions. At the time of writing, a number of key 
questions remain unanswered, but it is important to mention the ongoing uncertainty in 
the literature regarding the role of primary and secondary aptamer structure in 
recognition-based binding events. As single stranded oligonucleotides, aptamers are 
prone to forming secondary structures such as those found in single-stranded RNA 
(ssRNA) sequences such as the classic stem and loop structure, but is this secondary form 
necessary to facilitate specific binding, the lock-and-key model,
[12, 22]
 or do base 
interactions play the dominate role, leading to an induced fit
[26] 
of the aptamer's 
secondary structure in the presence of the non-nucleotide target as illustrated in Figure 
1.2.3. The answer is not as clear as most would like, but select studies have begun to 
draw links between the role structure and base interactions.
[27-29]
 Currently, the 
interactions are explained for each aptamer sequence in question, attributing the 
8 
 
specificity to interplay between stacking effects, shape complementarities, electrostatic 
interactions, or the formation of pseudo-base interactions using hydrogen bonds.
[24]
 
Aptamer affinity for a non-nucleotide target is quantified by measuring the equilibrium 
dissociation constant of the aptamer-target complex.
[23]
 A key focus and challenge of 
current aptamer research is the development of assays to accurately evaluate the affinity 
values for a give aptamer-target system 
 
Figure 1.2.3.  Schematic illustration of (top) lock-and-key and (bottom) induced fit 
binding between an oligonucleotide aptamer and its non-nucleotide target. 
 
 The identification of new oligonucleotide aptamers historically occurs through an 
in vitro process known as the systematic evolution of ligands by exponential enrichment 
(SELEX).
[30]
 SELEX is a combinational chemistry technique that may be optimized in 
various ways to allow for the selection of aptamers of greatly varying lengths and targets. 





Figure 1.2.4: A generalized schematic showing the key steps in a standard SELEX 
process.
[30]
The process begins with the generation of a random oligonucleotide library. 
The library is then incubated with the non-nucleotide target. Following incubation, any 
unbound oligonucleotides are removed and the bound aptamer candidates are eluted from 
the target. The recovered oligonucleotides are amplified using polymerase chain reaction 
(PCR), and the process is repeated for a chosen number of additional rounds, typically 
10-20. The final selected aptamer candidates are then recovered and sequenced to reveal 
their sequence identity. 
 
 SELEX is a cyclical process being with the generation of a large pool of random 
DNA sequences of an arbitrary size. The central randomized segment is flanked by 
constant primer binding regions at the 5’ and 3’ ends. Within a segment of base length, n, 
there exist 4
n
 possible sequences within the random library. This sequence diversity 
allows researchers to explore a number of candidate aptamer sequence; however the 
likelihood of exploring all possible sequences within a given SELEX experiment is 
unlikely as the length, n, is increased.
[31]
 Following the generation of the library, the 




oligonucleotides are removed, often by affinity chromatography or a similar process. 
Elution of the bound sequences is then followed by polymerase chain reaction (PCR) to 
exponentially amplify the bound aptamer candidates, doubling the amount of product for 
every cycle of PCR performed. This process can continue until the precursors, DNA 
primers and deoxynucleotide triphosphates (dNTPs) are exhausted. Subsequent rounds of 
the selection process are then performed and the stringency of the elution process is 
altered to narrow down the number of potential candidates to identify the highest affinity 
aptamer sequences. Aptamer candidates may then be analyzed and sequenced following 
the final round of SELEX. Additionally, counterSELEX cycles may be included to ensure 
that the aptamer specifically binds the target substrate rather than a material on which 
targets are immobilized to or molecules that are chemically or structurally similar to the 
desired non-nucleotide target. Modifications may also be made post-SELEX to adjust the 
affinity between an aptamer and target molecule using base deletions, mutations, or 
extensions.
[1, 24, 30] 
1.2.4 Thermodynamics of DNA in Solution 
 Duplex melting temperature are important to the understanding of the formation 
of DNA duplexes through hybridization of two complementary DNA strands. By 
convention, the melting temperature is defined as the temperature at which half of the 
duplexes are dissociated. Thus, the melting temperature serves as a measure of the 
thermal stability of the duplex and affinity of two strands for one another. Ionic strength 
of the solution, sequence composition, and strand concentration are all deciding factors in 
determining the melting point of an oligonucleotide system.
[32, 33] 
Melting temperature 
values can be tailored, for example, by adjusting the C/G and A/T base ratio. Higher 
amounts of C/G results in a higher melting temperature due to the three hydrogen bonds 
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formed between cytosine and guanine in comparison to the two hydrogen bonds formed 
between adenine and thymine. Ionic strength through salt additions affects the melting 
point by introducing counter ions for the negatively charged phosphate backbone of 
DNA. Thus, increasing the ionic strength will elevate the melting temperature by 
providing shielding and lowering the electrostatic repulsive interactions, as shown in 
equation 1, between DNA strands. The Gibb's free energy is a key thermodynamic 
“indicator” that takes into account many of these parameters by considering enthalpic and 
entropic contributions to the system. Additional considerations that are taken into account 




ΔG=ΔH-TΔS  (1) 
  This thermodynamic analysis can be extended to single stranded DNA (ssDNA) 
and serves as an indicator of the stability of intrastrand secondary structures such as 
hairpins and loops. DNA strands hybridize in an anti-parallel fashion, and thus ssDNA of 
sufficient base length can self-fold or self hybridize. Such interactions are important to 
consider during the selection of aptamers for this work because (1) the formation of 
homodimers between a population of particles all functionalized with identical DNA 
sequences DNA functionalized particles and (2) the formation of self hybridized or 
secondary intrastrand structures of the aptamer as well as (3) formation of aptamer-DNA 
duplexes must all be considered and monitored to insure the current experimental system 
functions correctly. Michael Zuker's UNAFold web-server is a powerful tool for this type 
of analysis, allowing calculation of all three values at varying temperatures and salt 
concentrations.
[35]
 This online thermodynamic calculator allows for rapid calculation of 
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DNA and RNA duplex melting temperatures and self melt temperatures and reports 
values for thermodynamic contributions to the Gibb's free energy for homodimer 
formation, self hybridization, and heterodimer hybridization. This online tool also 
displays any secondary structure that could feasibly be formed by the submitted 
sequence, and generates melting plots for the DNA system of interest.  
1.3 Vascular Endothelial Growth Factor as a Therapeutic Target 
1.3.1 Vascular Endothelial Growth Factor Structure and General Physiological 
Function 
 Vascular endothelial growth factor (VEGF) is one of numerous identified 
angiogenic growth factors.
[36]
 It’s homodimer structure is shown in Figure 1.3.1. In its 
native state VEGF is a heparin-binding homodimer glycoprotein, 45,000 Daltons in 
size.
[37, 38] 
It exists in a number of isoforms: VEGF165 VEGF121, VEGF189, VEGF206 are 
among the most common with VEGF165 being the major isoform.
[36]
 VEGF165 is basic in 
nature compared to the acidic VEGF121 isoform. The other two isoforms are more basic 
and bind heparin more readily. VEGF165 and VEGF121 are soluble proteins and a readily 
secreted from cells, though the VEGF165 has a significant fraction left bound to the 








Figure 1.3.1: Ribbon diagram of two vascular endothelial growth factor (VEGF) 
molecules (yellow and blue) in their antiparallel homodimer structure attached to 
two receptor molecules(green). Taken from Ferrara’s Vascular Endothelial Growth 




 The role of VEGF in angiogenesis and vasculogenesis is to stimulate formation of 
new blood vessels following injury, during embryonic development, or to bypass blocked 
vessels
[36, 38, 39] 
by promoting the migration and mitosis of endothelial cells to the injury 
site and initiating cell proliferation to build the necessary vasculature. Mutations or 
suppression of the VEGF gene have been linked to embryonic lethality in mice due to 
underdevelopment of organ vasculature and reduction in red blood cell nucleation. The 
effects are less pronounced in juvenile primates, leading only to suppression of the 
growth plate and ovarian angiogenesis.
[36]
 Gradients of VEGF are also linked to 
directional growth of longitudinal bones and cartilage invasion by blood vessels during 
skeletal growth and endochondral bone formation.
[40]
   
 
1.3.2 Role of Vascular Endothelial Growth Factor in Diseases 
 VEGF plays an important role in pathological angiogenesis. VEGF mRNA has 
been shown to be up regulated in human tumors. Vasculogenesis initiated by the over 
expressed growth factor allows tumors to grow and metastasize.
[39]
 Diabetes mellitus may 
result from neovascularization, leading to vitreous hemorrhages, detachment of the retina, 








A number of VEGF inhibitors have been developed to treat malignancy and help 
moderate gynecologic and ocular diseases. Thus far phase 2 and 3 trials have shown that 
VEGF inhibition may have a number of optimistic uses in future clinical treatments to 
minimize pathological angiogenesis, but further tests are needed to optimize such 
processes. An antibody-based therapeutic called Bevacizumab is the first such inhibitor 
clinically available in the United States. While other antibodies for growth factors exist or 
are still in development, Pegaptanib (or Macugen) is an example of an aptamer-based 
therapeutic that binds to VGEF. This angiogenic medication is used specifically to treat 
age-related macular degeneration (AMD) by binding the growth factor in the eye and 
acting as an agent to prevent formation of the vasculature responsible for the disease by 
reducing associated swelling and minimizing leakage from the blood vessels.
[42]
  
 Alternatively, VEGF itself may be desired as a therapeutic agent in cases such as 
coronary or limb ischemia in which restoration of blood vessel function is desirable. 
Current clinical treatments have not shown as significant results, but this may be due to 
under exposure in trials. Vascularization is a time dependent process, requiring more 
persistent exposure to VEGF to  allow the newly forming vasculature to fully develop 




1.4 Summary and Impact of Research 
 This thesis delves into the design and implementation of a colloidal delivery 
vehicle for the controlled uptake and release of vascular endothelial growth factor 
(VEGF). Preselected DNA aptamers are immobilized onto the surface of carboxylated 
microspheres, using 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride 
(EDAC) to form an amide bond between the aminated aptamer and functional groups. 
Through use of simple DNA mediated interactions, it is possible to selectively bind and 
release VEGF.
[3, 4, 12] 
At this point in time, aptamer research is still in its infancy 
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compared to the decades of devoted research to antibodies and thus the nature of the 
interaction between an aptamer and its target molecule is still unclear. To elucidate the 
nature of this interaction in the current work, primary and secondary hybridization of the 
aptamer sequences is studied and used implemented as a method to regenerate previously 
bound aptamers the goal of implementing a long term reusable delivery vehicle capable 
augmenting or even replacing current therapies such as chemotherapy. In order to expand 
the understanding of aptamer interactions, competitive binding and displacement of both 
VEGF and complementary soluble DNA sequences from particle-immobilized aptamers 
are investigated. We believe this work represents an important step forward in elucidating 
the binding nature of aptamers for their continued use in physiological systems as 
therapeutic agents. We investigate the effects of heat treatment, primary and secondary 
hybridization on a series of aptamer binding events to either VEGF or DNA targets.   
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OPTIMIZING APTAMER IMMOBILIZATION AND BINDING OF 
THE PRIMARY DNA TARGET 
  This chapter will detail the initial investigation into the immobilization of 
aptamer and DNA probe sequences onto microspheres and assess the ability of the 
immobilized aptamer sequences to bind to their primary DNA target. An EDAC coupling 
procedure is outlined , and the effects of aptamer concentration and incorporation of a 
secondary blocking agent are investigated. The focus of these studies was the 
optimization of binding of the aptamer sequences to DNA to verify hybridization activity 
of the aptamer and as a first step in designing a colloidal delivery vehicle capable of 
repeated binding and release events through simple DNA mediated interactions. 
Thermodynamic data for all of the sequences of interest is included as well as a study 
investigating the effects of heat treatment of aptamer-functionalized suspensions on 
hybridization. Ultimately, we uncovered handling parameters to maximize specific 
hybridization activity of the immobilized aptamers to specific DNA targets.  
2.1 Experimental Setup 
2.1.1 Aptamer and Complementary Target Selection 
 The aptamers used within this work were selected based on reports by Battig et 
al.
[1]
 and Hasegawa et al.
[2] 
Table 2.1.1 outlines the sequence information, including the 
function, name and sequence itself. The nomenclature is as follows: aptamers are named 
using two letters. The first letter corresponds to the molecule to which it binds: V for 
VEGF and A for ampicillin. The second letter is always an A to denote that it is an 
aptamer sequence. Complementary sequences add a C to this notation. For instance, 
VA1C corresponds to the primary DNA complementary target for the first VEGF 
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aptamer sequence, VA1. Additionally, a displacement agent (DA) sequence is used later, 
Chapter 5, to displace the primary DNA target. All noncomplementary sequences are 
denoted as NC followed by the number of total bases (e.g. NC14. The presence of a 
FAM label is denoted by *F following the sequence name.  Finally, a DNA probe and its 
complementary sequence were used as negative controls for nucleotide (this chapter) and 
non-nucleotide binding (Chapter 3). They use nomenclature outlined previously in our 
group.
[3] 
The immobilized probe sequence is denoted with an A and its base length. 
Complementary sequences are denoted with a B and the sequence length. Again *F 
following any sequence name indicates FAM- labeling of the 5' end of the DNA.  
Table 2.1.1: List of function, nomenclature, and sequences. All targets and displacement 
agents are soluble (i.e. not immobilized on microspheres), and the presence of a FAM 
dye molecule on the 5’ end is indicated with “*F” in the nomenclature. A toehold region 
on the 5' ends of the complementary targets is indicated by underlining the sequence and 
the polythymine spacer (between the particle surface and aptamer sequence segment) is 








VEGF aptamer 1 VA1              3'-GGGACGTGAGAACAGACCTTCTGCCCT10 -5' 
complementary target 
VA1C 
  5'-ACCTCCCTGCACTCTTGTCT -3' 
VA1C*F 
displacement agent DA   3'-TGGAGGGACGTGAGAACAGA-5' 
VEGF aptamer 2 VA2                3'-TGATAGACCGGGTGTGTGTAGGGCTGTCAT10-5' 
complementary target VA2C*F   5’–ACTCACTATCTGGCCCACAC – 3’ 
ampicillin aptamer AA                     3'-GGCGATATGTTGGCGGGCGT10-5' 
complementary target AAC   5'-AAAGGACCGCTATACAAC -3' 
DNA probe A20   3'-TAGTCGGCGTTAGGT6-5' 
complementary target B15*F   5′-ATCAGCCGCA ATCCA- 3' 
blocking agent T7 5'-TTTTTTT-3' 




  3'-GGATTGCGGCTGAT-5' 
  
  It is important to note that a single-stranded four base long toehold region was 
incorporated into the primary DNA targets, VA1C. The toehold, underlined in Table 1, 
was shown, using the UNAFold program
[4]
, to not inhibit primary hybridization or form 
any stable intrastrand secondary structures at room temperature (RT) as shown in Figure 
2.1.1. All DNA sequences were synthesized by Integrated DNA Technologies and 
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purified by the manufacturer using HPLC. 6-carboxyfluorescein (FAM) was used to 
fluorescently label complementary and noncomplementary sequences. The aminated 




Figure 2.1.1: Illustrated drawings adapted from UNAFold
 
based predictions of the most 
thermodynamically favorable secondary structures for the VEGF Aptamer 1 (VA1), 
VEGF Aptamer 2 (VA2), Ampicillin Aptamer (AA), and probe (A20). The self-melt 
temperature value,  and intrastrand hybridization Gibbs Free Energy (ΔGself) reported 
by Zuker’s UNAFOLD program
[4]
 are shown for each sequence. The thermodynamic 
values were calculated from Zuker’s Unified Nucleic Acid Folding (UNAFold) 
program
[4]
 (accessed on 9/16/2014), using 22 
o
C, 150 mM Na
+
, and 10 μM 
oligonucleotide concentration conditions wherever relevant. Bases in the sequences are 
color coded as follows: thymine (yellow), cytosine (red), adenine (blue), and guanine 
(green) and bond formation between Watson-Crick base matches and occasional guanine-
thymine bases is indicated with a single line between bases. 
 
 All chosen aptamers and the DNA probe were of similar base length. All aptamers 
shared commonalities in their predicted secondary structures (i.e. all possess hairpins as 
shown in Figure 2.1.1) to allow better comparisons between the samples. Figure 2.1.1 
also shows key thermodynamic data for each of the aptamer strands, namely the self 
melting point for the predicted secondary structures and the Gibbs free energy associated 




aptamer sequences were calculated to stably self fold, indicated by negative Gibbs free 
energy values; whereas, the DNA probe does not naturally favor self folding at RT. These 
sequences were selected to specifically evaluate different aspects of the binding 
interactions. Two VEGF aptamers, VA1 and VA2, were selected for comparison between 
aptamers for the same non-nucleotide target. A non-VEGF binding aptamer, AA, was 
selected with a similar structure to insure that the binding events observed were specific 
to aptamer sequences selected for VEGF and not due to nonspecific interactions with an 
oligonucleotide with a similar intrastrand structure. Finally, the DNA probe, A20, was 
selected to show that bases within linear (i.e. not slef-hybridized) DNA do not induce 
nonspecific binding of VEGF. A20 was also a convenient bench mark for the coupling 
reaction due to its vast prior use in the Milam lab.
[3, 5-7] 
2.1.2 Oligonucleotide and Particle Preparation 
Upon arrival all DNA sequences were aliquoted in TRIS-EDTA (TE) buffer. 
Aliquots were stored at 100 µM concentration at -20 
o
C. Unlabeled (VA1C, NC14, DA) 
and aminated DNA oligonucleotides (VA1, VA2, AA, A20, T7) were stored in pH 7.4 
TE, and fluorescein labeled sequences (VA1C*F, VA2C*F, B15*F, NC18*F, NC14*F) 
were stored in pH 8.0 TE. The 6-carboxyfluorescein (FAM) label is attached to the 5' end 
of the oligonucleotide via a three carbon linker. Amine terminal groups (-NH2) are 
attached to the 5' end using the same 3 carbon linker. Choice of aptamer sequences for 
VEGF are based on prior work by Hasegawa et al.
[2] 
and Battig et al.
[1]
 The choice of an 
aptamer sequence for ampicillin is based on the work of Song et al.
[8]
 As stated earlier, 
the nomenclature is as follows: the two VEGF aptamers are labeled VA1 and VA2; the 
ampicillin aptamer is labeled AA; complementary sequences to a particular aptamer are 
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denoted with the letter C (VAC1, VAC2, and AAC) as well as *F if labeled with a FAM 
moiety. Duplexes are indicated with a colon between sequence names (e.g. VA1:VA1C). 
Noncomplementary sequences are denoted by NC, their base length, and *F to denote the 
presence of a FAM label. The displacement agent, DA, is used to drive release of VA1C 
from VA1:VA1C duplexes. In addition to the ampicillin aptamer, AA, additional controls 
are run using a DNA probe, A20, along with its 15 base-long complementary sequence, 
B15. Finally, a 7 base-long polythymine sequence, T7, is used as a blocking agent to help 
cap any EDAC-activated sites not occupied by aptamer or probe (in selected cases). 
 100 µL of (1 µm dia.) carboxylated polystyrene microspheres (1% v/w ) from 
Bangs Laboratories, Inc. (Fishers, IN) are functionalized with DNA aptamer or probe by 
adding 200 µL of aminated oligonucleotides (2 µM in Tris-EDTA (TE) pH 7.4) and 25 
µL of a 1.0 M concentration of 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide 
hydrochloride (EDAC). DNA aptamer or probe coupling to particles was carried out in a 
similar manner reported previously by the Milam group
[6]
 as schematically represented in 
Figure 2.1.2. 
 
Figure 2.1.2: A schematic diagram illustrating crosslinking of carboxylated 
microparticles and aminated probe or aptamer sequences, using the carbodiimide 
molecule, EDAC. For simplicity only a single reaction is shown per particle. 
 For suspensions involving the blocking agent, T7, following a 2 h incubation of 




particles in the presence of EDAC, 100 µL of a second shorter, aminated sequence (T7, 
10 µM in TE pH 7.4) is added to conjugate any remaining EDAC activated sites on the 
particles and thus act as a "blocking agent" to reduce nonspecific binding events between 
the particle surface and targets (. Separate studies were carried out using 5 kDa aminated 
PEG (Sigma Aldrich, St. Louis, MO) as a blocking agent. Following the 1 h incubation 
with the T7 sequence or PEG, suspensions were centrifuged (9900g for 5 min) and 
resuspended in 100 µL of phosphate buffered saline containing 0.2% v/v Tween 20 
(PBS/T).  
2.1.3 Hybridization of DNA-Functionalized Particles and Analysis via Flow Cytometry 
 Samples for primary hybridization were prepared by taking 2 µL of the final 
coupling suspension and diluting it to 100 µL using PBS/T, yielding a 0.02 % particles by 
volume suspension. 100 µL of FITC labeled complementary DNA was prepared in TE 
pH 8.0 (2 µM) and added to the suspension. The resulting mixture was incubated at room 
temperature for 8-24 hrs on a rotomixer. Following incubation three washes were 
performed, centrifuging the samples at 9900xg for 3 min and resuspended in 100 µL 
PBS/T. The particles were then diluted to 1 mL using PBS/T. The 1 mL suspensions were 
analyzed on a Becton Dickinson LSR II flow cytometer (Becton Dickinson, San Jose, 
CA) using FACSDiva software (Beckton Dickinson). Calibration curves was generated 
using Quantum FITC-5 MESF standards (Bangs Laboratories) and were diluted in the 
same buffer as the samples, allowing quantification of fluorescence intensity in molecules 
of equivalent soluble fluorophore (MESF). MESF units from the standards are used to 
convert the mean fluorescence of each sample to the mean number of dye-labeled targets 
associated to each particle. Suspensions of EDAC-activated 1 µm PS microspheres, 
unactivated 1 µm PS beads, and DNA-functionalized 1 µm microspheres incubated with 
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a noncomplementary target were individually included to verify that binding of FAM-
labeled targets is due to specific interactions between complementary DNA sequences.  
2.2 Results and Discussion 
2.2.1 Analysis of Primary Hybridization Activity of Soluble Targets 
 Initially, five sets of particle suspensions (EDAC-activated beads with no 
immobilized DNA and A20, AA, VA1, and VA2-functionalized particles) were prepared 
to assess the nature of binding of the primary DNA target to the immobilized DNA 
aptamer and probe sequences. EDAC-activated microspheres were used to assess whether 
any nonspecific interactions occurred between the labeled DNA sequences and the 
microsphere's polymeric surface. A20, a well known sequence in the Milam group
[3, 5-7]
, 
was used as a benchmark for the coupling reaction's success since the protocol for this 
sequence has been previously optimized for DNA binding and release using a 
displacement agent.
[3]
 The ampicillin aptamer, AA, was included in this and later studies 
to verify that structurally similar aptamer sequences would not nonspecifically bind 
VEGF, and finally the two VEGF aptamer sequences, VA1 and VA2, were chosen to 
compare how changes in the binding interactions would affect different aptamers selected 
for the same non-nucleotide target. Initially, no blocking agent, T7, was immobilized on 
the surface alongside the aptamer sequence. Shown below in Figure 2.2.1 are the 
observed duplex densities for each of the five bead populations after an 8 h incubation  
with their respective complementary DNA targets. The inset shows the negative controls 
in which the five particle populations were each incubated with a noncomplementary 
FAM-labeled DNA sequence to verify that only complementary sequence interactions 





Figure 2.2.1:Surface densities of aptamer:DNA target duplexes of various aptamer-
functionalized (VA1, VA2, AA) microspheres with their complementary DNA targets 
(VA1C, VA2C, AAC). EDAC activated microspheres incubated with the AAC 
complementary DNA target is included as an additional control. The inset shows the 
same populations of aptamer-functionalized particles incubated with noncomplementary 
DNA targets (NC14*F and NC18*F) used as a negative control to evaluate the nature of 
DNA target binding. 
 
 The lack of fluorescent signal in the EDAC-activated case and all 
noncomplementary cases in the inset sharply contrasts to the remaining cases involving 
complementary sequences. Thus, Figure 2.2.1 indicates that all DNA aptamer and probe 
sequences were successfully immobilized and able to hybridize on the particle surfaces. 
Additionally, comparable results were achieved for each of the VEGF aptamer and probe 
sequences and thus further optimization of the coupling reaction appeared necessary to 
promote binding of the DNA target.  
 In an effort to minimize waste of excess aminated DNA, we chose to alter the 




being used for the coupling reactions. Originally, the standard protocol for EDAC 
coupling called for 100 µL of 10 µM DNA to yield a suspension containing 1.0 % 
functionalized particles (v/w). To verify if concentrations could be altered, three particle 
concentrations were tested: (1) the original concentration 1x (1.0%), (2) one fifth (1/5x) 
the standard concentration (0.2%), and (3) five times (5x) more concentrated (5.0%). 
Figure 2.2.2 shows the duplex densities observed when the coupling was performed using 
these three concentrations. EDAC activated microspheres without immobilized DNA and 
noncomplementary DNA target controls are also included to show that altering the 
particle concentration does not promote nonspecific binding. Given the good agreement 
between the 1x and 1/5x in terms of duplex density values, we chose to reduce the DNA 
concentration to 2 µM for all future coupling reactions to reduce DNA waste. 
 
Figure 2.2.2: Surface Densities of aptamer:DNA target duplexes of EDAC activated 
microspheres and VA1-functionalized particles and the VA1C*F complementary DNA 
target at various particle concentrations: 1% w/v (1X), 0.2% w/v (1/5X), and 5% w/v 
(5X). 
 
  While the coupling process had now been optimized for specific binding of the 
primary DNA target, the effects of DNA coupling on non-specific as well as specific 




results for VEGF binding; however, the key effects of these additional modification steps 
on hybridization of the complementary DNA target are outlined below. As shown in 
Chapter 3, VEGF was observed to nonspecificallybinding to the microspheres if 
incubated with microspheres a couple of hours following exposure to EDAC (intended to 
couple aminated DNA to carboxylated microspheres).. Therefore, we attempted to block 
off any remaining EDAC moieties  on the particles' surfaces through a delayed addition 
of another aminated macromolecule. Two such molecules were chosen for this purpose: 
(1) aminated polyethylene glycol (PEG) and an aminated polythymine DNA sequence 
(T7). PEG has been shown previously to sterically hinder nonspecific interactions
[9]
 in 
biological systems and to promote biostability,
[10]
 making it an excellent candidate to 
examine for  this colloidal system; however, the length of the chosen PEG molecule (5 
kDA in MW) could prevent specific interactions as well. T7 was chosen as an alternative 
blocking agent candidate since it too should be capable of to any remaining EDAC 
moieties without impeding interactions of either target molecule, DNA or VEGF, with 
the aptamer sequence. Which already includes a ten base long thymine spacer (T10) next 
to their immobilized 5' end. Since T7 is a seven base long polythymine sequence, its 
short base length should not sterically impede specific interactions (e.g. hybridization as 
examined here or VEGF binding as examined in Chapter 3). Moreover, its small size 
should help it penetrate through immobilized aptamers strands to interact with any 
remaining EDAC moieties.  
 Figure 2.2.3 shows the results of including PEG or T7 as a blocking agent on 
duplex formation. PEG and T7 were immobilized as described in the experimental 
section by incubating either aminated PEG or T7 with the EDAC activated particles 
28 
 
following a wash step after the initial 2 h incubation with the aptamer or probe sequences. 
As shown by the lower duplex density values in the PEG cases compared to the T7 cases 
for VA1, PEG significantly hindered the formation of duplexes between the immobilized 
VA1 sequence and its complementarty DNA target. These effects were less drastic in the 
second VEGF aptamer case, VA2; however, subsequent studies focused on the VA1 
system and thus further optimization appeared necessary in the absence of PEG as a 
blocking agent. Simple calculations of the size of the PEG chain for 5 kDA PEG 
molecule, using the ideal chain model as outlined in the Appendix showed that the PEG 
molecule was almost three times the length of the aptamer in its fully elongated state (i.e. 
not self-folded). Given the relatively larger size of PEG, it may sterically prevent the 
DNA target from reaching the aptamer sequence, preventing duplex formation. In 
contrast, T7 however showed far less of an effect on duplex formation for both VEGF 















Figure 2.2.3: Surface densities of aptamer:DNA target duplexes of VEGF aptamer 1 
(VA1) and VEGF aptamer 2 (VA2) functionalized microspheres in the presence (+) or 
absence (-) of polyethylene glycol (PEG) or a seven thymine blocking sequence (T7) on 




same microsphere suspensions and blocking agent conditions; however, incubations 
involved the noncomplementary DNA target (NC18). 
 
 Finally, the effect of annealing the aptamer-functionalized particles was 
evaluated. Theoretically, annealing the aptamer functionalized particles at 60 
o
C it should 
favor the formation of the predicted intrastrand secondary structures shown in Figure 
2.1.1. Many aptamers possess regions of self complementarity which may inhibit 
hybridization with complementary targets, but could potentially promote homodimer 
formation (e.g. between two aptamer-functionalized particles) in the absence of 
complementary DNA. Figure 2.2.4 shows UNAFold predicted structures for homodimer 
formation between identicle aptamer species. Also included are the Gibbs free energy 















Figure 2.2.4: Schematic illustration of homodimer formation between pairs of identical 
VEGF aptamer 1 (VA1), VEGF aptamer 2 (VA2), ampicillin aptamer (AA), and DNA 
probe (A20) sequences, based on predictions by Zuker's Unified Nucleic Acid Folding 
(UNAFold) program
[4]
 accessed on 9/16/2014 using 22
o
C, 150 mM Na
+
, and 10 μM 
oligonucleotide concentration conditions wherever relevant. Bases in sequences are 
color-coded as follows: thymine (yellow), cytosine (red), adenine (blue), and guanine 
(green). 
 
 Each of the sequences utilized in this work can theoretically form homodimers, as 




homodimers, in turn, can lead to aggregation of the colloidal particles. To examine 
aggregation in aptamer-functionalized microsphers, flow cytometry was utilized. Flow 
cytometry utilizes forward scatter (FSC) and side scatter (SSC) to cluster populations of 
similar size and shape. FSC corresponds to the overall size of the particle and SSC gives 
a measure of the surface complexity of the analyzed particle. Using these values a scatter 
plot can be generated that separates populations of colloidal particles by size and 
complexity.  Figure 2.2.5(a) shows a scatter plot taken from an early flow cytometry 
experiments during these optimization attempts for aptamer-functionalized (VA1) 
particles in which three separate populations of particles are gated. These populations 
correspond to (P1) singlets (individual particles), (P2) doublets (aggregates of two 
particles), and (P3) multiple-particle aggregates such as triplets.  Figure 2.2.5(b) shows 
VA1-functionalized particles following annealing treatment at 60 
o
C. Here, far more 
particles appear as singlets indicating that annealing appears to reduce aggregation (i.e. 
increase P1 from 40 % on average (Figure 2.2.5(a) to  85 % on average (Figure 2.2.5(b)), 
due, most likely, to a reduction in homodimer formation and an increase in the self-
hybridized structures in single-stranded aptamers. While this stability in the aptamer-
functionalized particles is desirable, we must still test if duplex formation is still 
favorable in these annealed suspensions. These experiments are discussed next. 
Figure 2.2.6 shows the observed duplex densities of VA1, VA2, and AA-
functionalized particles if no heat treatment has been performed (no anneal case, NA), if 
the particles were annealed prior (PA) to incubation with their DNA target, and if 
annealed during (AD) the first 30 min of the incubation with the primary DNA target. 
















Figure 2.2.5:  Scatter plots from flow cytometry analysis of VA1-functionalized 
microspheres of forward scatter (FSC-A) vs. side scatter (SSC-A) of annealed aptamer-
functionalized (VA1) microspheres before (a) and after (b) the suspensions were 
annealed. Points shown in the gated P1 population correspond to the singlet population of 

















Figure 2.2.6: Surface densities of aptamer:DNA target duplexes of various VEGF 
aptamer 1 (VA1), VEGF aptamer 2 (VA2), and ampicillin aptamer (AA) functionalized 
microspheres under three annealing conditions: no anneal (NA), annealed prior (PA) to 
incubation with the complementary DNA target (VA1C*F or VA2C*F), and annealed 
during (AD)  incubation with the complementary DNA target. The controls shown in the 
inset contain data for the same microsphere suspensions and annealing conditions; 






As shown in Figure 2.2.6, annealing had various effects on the aptamer:DNA 
target duplex density values between the aptamers and their complementary DNA targets. 
For particles functionalized with VA1 or AA the addition of an annealing step only 
slightly increased the duplex density. In contrast, formation of duplexes with VA2-
functionalized particles was significantly hindered by adding an annealing step. The stark 
difference in responses from the two VEGF aptamers may be explained by examining 
their predicted secondary structures. As seen in Figure 2.1.1, VA1 and VA2 both 
theoretically form a simple hairpin loop structure, but there is one noticeable difference 
between them. The longer hybridized stem in VA2 may hinder duplex formation with the 
complementary DNA target since the DNA target must successfully invade and 
overcome this self-hybridized stem to form a duplex.  
2.3 Conclusions 
 It was shown that binding of the primary DNA target was optimized by 
decreasing the DNA concentration during the coupling reaction to minimize wasted 
DNA. Comparable duplex densities to the optimized A20 DNA probe coupling reaction 
were achieved, and the inclusion of a blocking agent, T7, was shown to not significantly 
hinder duplex formation, allowing it to be used to optimize VEGF binding events in 
subsequent studies highlighted in Chapter 3. Heat treatment of aptamer-functionalized 
microspheres was shown to increase the singlet population, possibly due to favoring 
formation of the predicted intrastrand secondary structure for the aptamer sequences 
rather than homodimer formation between opposing aptamer-functionalized particles. 
These dispersed particles also allow more of the immobilized aptamers available to bind 
their DNA or non-nucleotide targets.  Finally, it was shown that each aptamer may have 
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to be optimized for future systems incorporating multiple aptamer sequences to achieve 
multipurpose delivery. This was made apparent when the inclusion of the annealing 
process significantly hindered binding of the primary DNA target for the second VEGF 
aptamer sequence (VA2), but had little beneficial effect for the first VEGF aptamer-
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OPTIMIZING SPECIFC BINDING OF VEGF BINDING TO VEGF 
APTAMER FUNCTIONALIZED COLLOIDAL PARTICLES  
Introduction 
 
 This chapter will detail the experiments to quantify the binding activity of VEGF  
to aptamer-functionalized microspheres. The initial experiment’s focus centers heavily on 
the steps made to minimize nonspecific binding of VEGF to the EDAC moieties left 
behind after the aptamer coupling reaction. Outlined within are flow cytometry assays to 
measure bound VEGF using a multicomponent labeling scheme, and a Luminex-based 
assay to measure the unbound VEGF remaining in supernatant (following incubation 
with aptamer-functionalized particles) is also discussed.  
3.1 Experimental Setup 
3.1.1 VEGF Preparation and quantification via Luminex Analysis  
 10 µg of VEGFA (GeneTex, Inc.) was suspended in phosphate buffer saline 
containing 0.5 % w/v bovine serum albumin (PBS/BSA). The PBS/BSA was prepared by 
weighing out 250 mg of BSA and disolving it in 50 mL of PBS. The resulting solution 
was then denatured using a 60
 o
C water bath over 30 min.
[1]
 The denatured BSA is 
intended to work in the same manner to help block the particle surface from nonspecific 
binding of VEGF to the functionalized particles. Luminex analysis was then performed to 
verify the concentration of VEGF in solution. Using a Luminex cytokine kit (Bio-Rad, 
Hercules, CA) magnetic beads functionalized with VEGF antibodies were prepared from 
the supplied stock of beads (10x v/v). The stock beads were vortexed for 30 sec and then 
576 µL were added to 5184 µL of the Bio-Plex assay buffer from the kit. The beads were 
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then vortexed for an additional 30 sec, wrapped in aluminum foil to protect from 
exposure to ambient light, and allowed to equilibrate to room temperature. 50 µL of the 
diluted beads were added to each of the wells of a 96 well plate and washed three times 
with a Bio-Plex Pro Magnetic Wash Station, allowing 60 sec for pelleting to occur, and 
resuspended in 100 µL of the kit's wash buffer. 50 µL of each sample was then added to 
the appropriate wells. The plate was covered with parafilm and incubated on a shaker at 
850 rpm for 1 hr at room temperature. During the incubation, the Bio-Plex detection 
antibodies were prepared to label the bound VEGF according to the protocol supplied 
with the kit, following the equations below.  
Vab = n * 2.5 µL * 1.25  (1) 
Vdilutent = n * 22.5 * 1.25   (2) 
In which Vab is the volume of the stock antibody solution needed, Vdilutent is the volume of 
the antibody dilutent needed, and n is the number of wells used on the plate. The plate 
was then washed three times, using magnetic separation and the wash buffer supplied 
with the kit, before being resuspended in 25 µL of the diluted antibody solution and 
allowed to incubate for 30 minutes. The antibody used was biotinylated, allowing for 
labeling using a streptavidin associated phycoerythrin (SA-PE) polymer. Following the 
30 min incubation, the plate was washed again three times and resuspended in 50 µL of 











Figure 1.1.1: Schematic diagram to illustrate the series of components used to label 
VEGF bound to its aptamer as shown or bound in a nonspecific manner to an unrelated 
oligonucleotide or the underlying particles substrate (not shown). 
 
The SA-PE was prepared according to the Bio-Plex protocol using the following 
equations. 
VSA-PE = n * 0.5 µL * 1.25   (3) 
Vassay = n * 49.5 µL * 1.25   (4) 
VSA-PE is the volume of the SA-PE stock solution. Vassay is the volume of the assay buffer 
needed, and n is again the number of wells used in the 96 well plate. A 10 minute 
incubation is performed at room temperature, and the plate is washed a final three times. 
The samples are then resuspended in 100 µL of the assay buffer provided in the kit and 
the Luminex is run. Alongside the VEGF stock solution, a set of cytokine group I 
standards were run. The standards contain dried preweighed amounts of each of the group 
I cytokines, including VEGF. The standards are reconstituted in 500 µL of PBS/BSA and 
lightly vortexed for 5 sec. The vile is then placed in an ice bath for 30 min until ready for 
dilution. 72 µL of the reconstituted standard are added to 128 µL of PBS/BSA and a 4 
fold serial dilution is performed to generate 8 tubes of decreasing concentration. The 
standards are prepared in the same way as the samples for Luminex and allow for 




particles using a standard curve and fit. All measurements were performed on a Luminex 
100/200 system (Luminex Corp, Austin, TX). 
3.1.2 Preparation of DNA-Functionalized Particles Bound with VEGF Target and 
Analysis via Flow Cytometry 
 For the analysis of VEGF binding (shown in Figure 3.1.1), 100 µL of aptamer or 
probe-functionalized particles (diluted to 0.02% w/v with PBS/T) were first centrifuged 
(9200g for 5 min) and then resuspended in 100 µL of 0.5% w/v  PBS/BSA three times. 
One of two heat treatments were applied to the aptamer or probe functionalized particles: 
VEGF was added at room temperature (RT) for 8 h (1) after the DNA aptamer or probe 
coupling reaction was terminated (no anneal case) or (2) after the suspension was 
warmed to 60 
o
C for 30 min, then cooled to RT in an HB-1000 hybridizer oven (UPV, 
LLC, Upland, CA) for 45 min. Notably, annealing aptamer functionalized particles in the 
absence of any target is intended to favor formation of the predicted intrastrand 
secondary structure at RT as shown in Figure 2.1.1. For these VEGF binding studies, 100 
µL of soluble VEGF (2 µM in PBS/BSA) is incubated with the aptamer or probe-
functionalized particles for 8 h. Following incubation, suspension were centrifuged 
(9900g 5 min) three times and resuspended in 100 µL of PBS/BSA. Then components 
from the BioPlex Pro Assay kit are added in a sequential manner (per kit instructions) to 
bound VEGF as illustrated in Figure 3.1.1. In brief, a biotinylated detection antibody that 
binds to the receptor binding site of the VEGF was added (followed by 3 washes in 




VEGF binding to DNA-functionalized particles was directly quantified using flow 
cytometry. Samples were prepared as previously described
[2]
 by diluting the resulting 100 
µL  suspensions to 1000 µL  using PBS/BSA. Conversion of fluorescence intensity 
values to either Molecules of Equivalent Soluble Fluorophore (MESF) (for bound PE-
labeled VEGF) was accomplished using the Quantum R-PE  MESF standard (Bangs 
Laboratories, Fishers, IN) diluted in the 500 µL of PBS/T buffer. All standards and 
samples were run on a DB LSR II Flow Cytometer (Becton Dickinson, San Jose, CA). 
BD FACSDiva software was utilized for data acquisition. Samples evaluated included 
aptamer functionalized particles (1) alone (to measure autofluorescence background) and 
(2) incubated with VEGF(to measure fluorescence associated with the formation of 
aptamer:VEGF complexes. 
 
3.2 Results and Discussion 
3.2.1 Analysis of VEGF Binding using Luminex 
 The Luminex detection system (Luminex Corp, Austin, TX) is a high throughput 
flow cytometry system built around three core features. First, fluorescently dyed 
microspheres (Bio-Rad, Hercules, CA) are prepared by the manufacturer to possess a 
distinct fluorescent color code or spectral address. This permits discrimination between 
multiple bead types in a multiplex suspension. Second, it utilizes a specific or dedicated 
flow cytometer with appropriate lasers and optics to measure bound molecules to these 
specific particles. This point is important since a user cannot emply their own choice of 
microspheres to directly assess bound species. Instead one uses these specialized beads to 
capture any remaining species in the supernatant as illustrated in Figure 3.2.1. Thus, one 
indirectly assesses the amount of bound species in their own suspensions by analyzing 
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the supernatant with these specialized beads.Third, the system has a high speed processor 
for managing the accumulated fluorescence data. This setup allows for rapid 
simultaneous analysis of complex systems containing more than 100 different bead 
types.
[3]
 Using a Bio-Rad kit designed for VEGF, Luminex analysis was performed on 
the VEGF stock solution (to provide a calibration curve) and then on the VEGF 
remaining in suspension following incubation with aptamer functionalized beads (shown 
in Figure 3.2.1). 
 
Figure 3.2.1: A schematic representation outlining the preparatory steps for capture and 
analysis of VEGF remaining in solution for the Luminex. Following incubation with the 
aptamer-functionalized microspheres, VEGF molecules remaining in solution are 
incubated with magnetic particles functionalized with VEGF antibodies. Then a series of 
labeling components, including a second soluble biotinylated VEGF antibody and a 
streptavidin associated PE molecule are incubated with magnetic particles to tag any 
antibody bound VEGF. 
 
 Figure 3.2.2 shows the results from a calibration standard (Bio-Rad, Hercules, CA) 
prepared for human group I cytokines, including VEGF. A premeasured amount of 
VEGF was dissolved within PBS/BSA to prepare the initial standard and 4-fold dilutions 
were executed to measure the fluorescence intensity associated with five known 
concentrations to generate the calibration shown in Figure 3.2.2(a). Trend lines were 
applied to the full eight point standard curve and to the 4 points, corresponding to the 
lowest concentration standards. This was done to insure a better fit at the four lower 





Figure 3.2.2 Calibration curve for VEGF concentration generated using the Bio-Plex Pro 
Human Cytokine Standard 27-Plex, Group I from Bio-Rad. (a) The full curve for all 8 
standards prepared using serial dilution as per kit instructions. (b) The four lowest 
concentrations are shown to establish a linear relationship between concentration and 
fluorescence intensity.  
 
 Table 3.2.1 shows raw data used to create the calibration curves shown in Figure 
3.2.2. Standards were prepared from a reconstituted vial containing measured amount of 
human group 1 cytokines. A fourfold dilution was performed between each standard, 
using PBS/BSA, according to the kit's protocol. Also listed in Table 3.2.1 is the 
fluorescent intensity across 50 randomly samples particles in suspension by the luminex 
system, the expected concentrations of VEGF for each standard based on the initial 
concentration of VEGF in standard S1, and the concentrations calculated using the 















Table 3.2.1: Standard data from the luminex analysis of Human Cytokine Group 1Standards from Bio-Rad 
for the Bio-Plex system, using a fourfold serially diluted reconstituted standard 
containing a measured amount of VEGF and other cytokines. List are the standards 
designation number during serial dilution, the mean fluorescent intenstity measured by 
the Bio-Plex system, the expected concentration of VEGF in each dilution based on the 
original weighed amount of VEGF present in standard S1, and the calculated 
concentration from the generated calibration curves. 
Standard Mean Fluorescent Intensity Actual Concentration (M) Calculated Concentration (M) 
S 1 19239 3.59E-05 3.82E-05 
S 2 11232 8.97E-06 8.71E-06 
S 3 4284 2.24E-06 2.10E-06 
S 4 1589 5.6E-07 5.51E-07 
S 5 397 1.4E-07 1.39E-07 
S 6 119 3.5E-08 3.89E-08 
S 7 31 8.76E-09 7.03E-09 
S 8 14 2.19E-09 1.02E-09 
  
 Using the calibration curve we then attempted to measure the amount of VEGF 
bound to aptamer functionalized particles. As outlined above, samples were prepared, 
allowing VEGF to incubate with the aptamer functionalized particles for 8 hrs prior to 
beginning the luminex study. Samples were prepared using pM concnetrations of VEGF 
based on estimates of amount of aptamer available for binding VEGF. To estimate the 
amount of aptamer and VEGF, we used the primary hybridization duplex density 
previously reported in Figure 2.2.2 and assumed the aptamer-to-bound VEGF ratio. The 
system was designed for 50 % binding of VEGF initially, to create an easily detectible 
change in VEGF supernatant concentration because the luminex was used to examine the 
VEGF that did not bind and was left behind after washing and removing the supernatant 
from the beads (Figure 3.2.1). Other groups had previously reported being able to 
measure concentrations in the pM range, but we were not able to distinguish between 
solutions without any VEGF present and the stock VEGF solution (12.11 pM), as shown 





Figure 3.2.3 Concentrations of VEGF in solution converted from the measured average 
fluorescent intensity for H2O, PBS/T, PBS/BSA, and a 12.11 pM VEGF stock solution 
using the Luminex kit from Bio-Rad. H2O, PBS/T, PBS/BSA were samples without 
VEGF present in solution. 
 
 A reoptimization was attempted for nM concentrations of VEGF, since the 
standards showed better fidelity between the calculated and expected concentrations 
within this range. Figure 3.2.4 shows the results from this reoptimization. Both trend 
lines shown above were used in calculating the concentrations, and the calculation based 
off the lower four points is denoted as low conc and shown in red. Despite reoptimizing 
the system for the higher concentrations, the experiment failed, showing no binding for 
both the VEGF aptamer (VA1) and the negative control, ampicillin aptamer (AA). Any 
further changes the the experiment would have required working with multiple milliliters 
of coupled beads, a costly and time consuming experiment, so the Luminex study was 
forgone and an alternate analysis technique was used, involving the luminex labeling kit 




Figure 3.2.4 Converted VEGF concentrations using the Luminex instrument. Analysis 
was performed on the VEGF remaining in supernatant following incubation with the 
indicated aptamer functionalized beads and compared to the stock 10 nM VEGF solution.  
 
3.2.2 Analysis of VEGF Binding using Flow Cytometry 
 Flow cytometry was used as an alternate to measure relative amounts of bound 
VEGF. Notably, no calibration standards are available for converting fluorescence 
intensity values tino amounts of bound VEGF due to the polymeric nature of the PE label 
(with multiple dye molecules). VEGF165 the major isoform of VEGF, possesses two 
binding sites: a heparin binding domain and a cell receptor binding domain.
[4, 5]
 The two 
VEGF aptamers used in this work reportedly to bind to the herapin binding domain, 
leaving the receptor binding domain free to be accessed by the biotinylated detection 
antibody from the luminex kit.
[5, 6]
 The kit was optimized for a 1.0 % population of 
aptamer-functionalized microspheres. A more concentrated microsphere volume was 
employed than what is typically used for flow cytometry according to enable use of the 
Luminex kit to label the aptamer-bound VEGF for flow cytometry. Figure 3.2.5 shows 
the results from the initial trial of the labeling process for flow cytometry. Three different 
concentrations of VEGF were analyzed to determine if a detection limit existed for this 
labeling technique: 10 µM, 10 nM, and 10 pM. No binding was detected for the nM and 
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pM concentrations, but a significant amount of binding was observed of the 10 µM case, 
as indicate by the nonzero MESF value associated with PE-labeled bound VEGF. 
 
Figure 3.2.5 Molecules of equivalent soluble fluorophore MESF associated with PE-
labeled VEGF bound to immobilized VA1 at three concentrations of VEGF: (1) 10 µM, 
10 nM, and 10 pM 
 
 Now that the 10 μM detection limit has been established to quantify bound VGEF 
(whether specific or nonspecific) using flow cytometry, it was now necessary to 
minimize any nonspecific binding of VEGF. VEGF binding to the aptamer-
functionalized microspheres without the T7 blocking sequence was analyzed next. 
Significant VEGF binding was observed (Figure 3.2.6) for the A20, AA, and EDAC 
activated 1 µm PS particles in the absence of T7. Though more VEGF binding was 
observed for the VA1 case, it is evident that nonspecific binding is significant in these 
suspensions. There was one exception to the outcome. The lack of any fluorescence 
associated with VEGF bound to the unactivated (i.e. carboxylated) beads indicates that 
one source of nonspecific interactions could be the EDAC moeities left behind after 
aptamer coupling. EDAC reportedly has a short lifespan in solution
[7]
 but appears to 
remain active on the particle surface after converting the carboxyl functional groups to 
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intermediates. This fact was confirmed in separate experiments to be discussed in Figure 
3.2.7. The T7 blocking agent was introduced in an attempt to exhaust these moeitites.  
 
Figure 3.2.6: Molecules of Equivalent Soluble Fluorophore (MESF) measured from 
phycoerythrin (PE) labeled VEGF bound to various bare (unactivated), EDAC incubated 
(Activated), and DNA (A20, AA, and VA1) functionalized microspheres in the absence 
(T7(-)) or presence (T7(+)) of a short, seven thymine blocking agent. Controls shown in 
the inset show the same microsphere suspensions incubated with PE label, but in the 
absence of any VEGF. 
 
 As shown in Figure 3.2.6, the amount of fluorescence associated with VEGF 
binding decreases in every DNA-functionalized suspension case. Thus, incorporation of 
the T7 blocking sequence appears to serve to reduce but not elminate nonspecific binding 
Having confirmed the partial success of the T7 blocking agent, we decided to test the 
lifespan of EDAC on the particle surface. To accomplish this, the coupling reaction was 
repeated, but DNA was introduced to the solution at different time points (0-4 h) after the 
particles had been exposed to EDAC. The first three time points (0-2 h) correspond to the 
length of the standard coupling protocol with the first aminated DNA sequence (e.g. 
aptamer). The 2 h timepoint corresponds to the introduction of the aminated T7 sequence. 
The fourth time point (3 h) corresponds to the end of the blocking agent's incubation with 




remain active, even after all aptamer and blocking agent incubation periods. Figure 3.2.7 
shows the significant duplex densities achieved with the delayed additions of aminated 
sequence results from this study, indicating that EDAC moieties remain active for over 4 
hours despite the reported short lifetime of EDAC.  
 
Figure 3.2.7: Surface densities of the ampicillin aptamer:DNA target duplexes following 
incubation with FAM-Labeled complementary DNA target (AA:AAC*F). The aptamer 
(probe) sequences were introduced to the EDAC activated particles at the 0, 1, 2, 3, and 4 
h time points to evaluate EDAC viability over time. 
 
 In light of these time studies with EDAC and delayed addition of aminated DNA 
that still effectively coupled to the particles, concerns that amine groups on VEGF could 
couple to any remaining EDAC moieties on the aptamer-funcionalized particles were 
raised. To examine the combinded effect of including the T7 blocking agent as well as an 
overnight aging step prior to VEGF addition, all future samples were aged for 8 hrs 
overnight to further exhaust the lifespan of the EDAC moieties. Particles functionalized 
with VA1, VA2, or AA were prepared aged before they were incubated with VEGF. 
Figure 3.2.8 shows the results of  this study and shows significant fluorescence due to 
VEGF binding occuring only in the two VEGF aptamer cases, and not in the negative 





Figure 3.2.8: Molecules of Equivalent Soluble Fluorophore (MESF) measured from 
phycoerythrin (PE) labeled VEGF bound to VEGF Aptamer 1 (VA1) , VEGF Aptamer 2 
(VA2) and ampicillin aptamer (AA) functionalized microspheres 8 h after the completion 
of the coupling reaction. Controls shown in the inset show the same microsphere 
suspensions incubated with the PE label in the absence of any VEGF. 
 
  As an added control shown in the inset of Figure 3.2.8, samples that were 
unexposed to VEGF but otherwise were exposed to the full labeling steps to verify that 
labeling components themselves do not bind to particles in the absence of VEGF. No 
fluorescence was observed in these controls, indicating that the observed fluorescence 






Figure 3.2.9: Molecules of Equivalent Soluble Fluorophore (MESF) measured from 
phycoerythrin (PE) labeled VEGF bound to VEGF Aptamer 1 (VA1) and ampicillin 
aptamer (AA) functionalized microspheres under two annealing conditions: no anneal 
(NA) and annealed prior to VEGF incubation (PA). Controls shown in the inset show the 
same microsphere suspensions incubated with the PE label in the absence of any VEGF.  
 
 Finally, the effects of annealing on VEGF binding were examined. Without the 
extra annealing step, these particles were more prone to aggregation possibly due to 
interparticle interactions between homodimers of the immobilized aptamer sequences 
(FIgure 2.2.5). Additionally, VEGF binding itself may require the aptamer to adopt its 
single stranded secondary structure.
[8, 9]
 The anneal should favor the formation of the 
stem and loop structure predicted by the UNAFold
[10]
 webserver and shown in Figure 
2.1.1. Annealing the functionalized beads prior to introduction fo the VEGF solution did 
show a noticeable increase in binding for the VEGF aptamer case, but not to ampicillin 
aptamer-functionalized particles. Thus annealing the VA1-functionalized particles 
appears to further enhance only specific bidning of VEGF as shown in Figure 3.2.9. 
3.3 Conclusions 
 Binding of the non-nucloetide target, VEGF, to the aptamer-functionalized 
particles was optimized by minimizing nonspecific binding and maximizing specific 




minimized by incorporating a blocking agent, T7, into the coupling reaction. This 
aminated sequence further exhausted remaining EDAC moieties on the particle surface, 
but it was also necessary to age the particles for a minimum of 8 h to significantly 
eliminate nonspecific interactions. Finally, specific interactions were enhanced by 
annealing the aptamer-functionalized particles. This annealing process likely favors the 
formation of singlet populations of  dispersed VA1 aptamer-functionalized particles and 
self folding of the aptamers into their predicted single stranded secondary structures.  
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COMPETITIVE BINDING OF VEGF AND COMPLEMENTARY 
DNA TO APTAMER FUNCTIONALIZED COLLOIDAL 
PARTICLES 
Introduction 
 This chapter focuses on the studies investigating the dual nature of aptamer 
binding. Aptamer-functionalized particles are coincubated with both primary targets, 
DNA and VEGF, or serially incubated with the two targets. Samples are prepared using 
one of three heat treatments: no anneal (NA), using the coupled beads after aging for 8 
hrs; preannealed (PA), where the particles are brought to 60 
o
C and cooled to room 
temperature (RT) before incubation of either primary target; and annealed during (AD), 
where the samples are taken to 60 
o
C for 30 min with the complementary DNA present in 
solution and then allowed to cool naturally to room temperature over the remainder of the 
incubation. There are three key studies included within this chapter: the effects of 
hybridization on VEGF binding activity, the effects of VEGF binding on hybridization, 
and the effects of coincubating equal concentrations of DNA and VEGF introduced to the 
aptamer functionalized particles together.  
4.1 Experimental Setup 
4.1.1 Competitive Binding and Displacement Sample Preparation 
 Upon completion of the functionalization of the microspheres with the aptamer or 
probe and blocking agent, suspension were heat-treated (described in the next paragraph) 
and then incubated with either its VEGF target (see Figure 4.1.1a), its DNA target (see 




Figure 4.1.1: Illustration of aptamer-mediated binding of VEGF and/or DNA targets. 
Aptamer-functionalized microspheres are incubated with (a) VEGF alone and then (b) 
unlabeled or labeled DNA target; (c) VEGF and unlabeled or labeled DNA target 
simultaneously; (d) unlabeled or labeled DNA target alone and then (e) VEGF. 
 
 For the analysis of VEGF binding (shown in Scheme 4.1.1a), 100 µL of aptamer 
or probe-functionalized particles (diluted to 0.01% w/v) were first centrifuged (9200g for 
5 min) and then resuspended in 100 µL of 0.5% w/v  PBS/BSA three times. One of two 
heat treatments were applied to the aptamer or probe functionalized particles: VEGF was 
added at room temperature (RT) for 8 h (1) after the DNA aptamer or probe coupling 
reaction was terminated (no anneal case) or (2) after the suspension was warmed to 60 
o
C 
for 30 min, then cooled to RT in an HB-1000 hybridizer oven (UPV, LLC, Upland, CA) 
for 45 min. Notably, annealing aptamer functionalized particles in the absence of any 
target is intended to favor formation of the predicted intrastrand secondary structure at 
RT as shown in Figure 2.1.1. For these VEGF binding studies, 100 µL of soluble VEGF 
(2 µM in PBS/BSA) is incubated with the aptamer or probe-functionalized particles for 8 
h. Following incubation, suspension were centrifuged (9900g for 5 min) three time and 
resuspended in 100 µL of PBS/BSA. Then components from the Bio-Plex Pro Assay kit 
are added in a sequential manner (per kit instructions) to bound VEGF as illustrated in 




site of the VEGF was added (followed by 3 washes in PBS/BSA), then streptavidin-PE 






Figure 4.1.2: Schematic diagram to illustrate the series of components used to label 
VEGF bound to its aptamer as shown or bound in a nonspecific manner to an unrelated 
oligonucleotide or the underlying particles substrate (not shown). 
 
   Samples for hybridization of the primary DNA target, shown in Scheme 4.1.1d, 
were prepared by adding 100 µL of FAM-labeled DNA target at 2 µM to 100 µL of 
aptamer or probe-functionalized particles (0.1% w/v) for 8 h at RT. Following incubation 
with DNA target samples were washed by centrifugation (9900g 3 min) and resuspended 
in 100 µL PBS/T three times.  
Coincubation of primary targets was performed using equal concentrations (2 
µM) of the FAM-labeled DNA and VEGF targets as shown in Scheme 4.1.1c. 100 µL of 
the DNA and VEGF suspension were added to 100 µL of 0.1% w/v of DNA-
functionalized particles for 8 h. Following incubation three washes were performed by 
centrifuging the particles (9900g 3 min) and resuspending the particles in 100 µL of 
PBS/BSA. Samples for the analysis of the effects of serial incubation of both primary 
targets were prepared using the appropriate heat treatment as described above and then 
incubated with either VEGF or the complementary DNA for 8 h as previously described. 
Following the initial incubation three washes were performed by centrifuging (9900g 5 




with FAM-labeled DNA (100 µL at 2 µM in TE pH 8.0)  second or 100 µL PBS/BSA 
when incubating with VEGF (100µL at 2 µM in PBS/BSA) second. The second target, as 
shown in Scheme 4.1.1b and 4.1.1e, is then added to the suspension for 8 h.  
All samples were prepared for analysis using flow cytometry as previously 
described by the Milam lab.
[1] 
The particle suspensions were diluted to 1 mL using PBS/T 
following three washes (centrifugation at 9900xg for 3 min and resuspended in 100µL 
PBS/T) . The 1 mL suspensions were analyzed on a Becton Dickinson LSR II flow 
cytometer (Becton Dickinson, San Jose, CA) using FACSDiva software (Beckton 
Dickinson). Calibration curves was generated using Quantum FITC-5 MESF standards 
(Bangs Laboratories, Fishers, IN)  or Quantum R-PE  MESF standard (Bangs 
Laboratories, Fishers, IN) and were diluted in the same buffer as the samples, allowing 
quantification of fluorescence intensity in molecules of equivalent soluble fluorophore 
(MESF). MESF units from the standards are used to convert the mean fluorescence of 
each sample to the mean number of targets associated to each particle. For suspensions of 
EDAC-activated 1 µm PS beads, unactivated 1 µm PS beads, and DNA functionalized 
beads mixed with a noncomplementary target were included to verify that all 
hybridization corresponds to specific interactions between complementary DNA 
sequences. 
4.2 Results and Discussion 
4.2.1 Analysis of the Effects of Coincubation and Serial Incubation on the Binding of the 
Primary Targets 
 With nonspecific interactions minimized for the colloidal system, the next step 
was to evaluate the interplay between the two targets. VA1 has previously been included 
in a triggered release system by Battig et al.
[2]
However, that system had the aptamer 
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sequences embedded inside a water swelled hydrogel matrix and focused on 
characterizing the release of the target protein molecules. Instead, we discuss directly 
measuring the amount of bound target to particle-immobilized aptamer sequences. To 
accomplish this we (1) individually incubated one type of particle; (2) coincubated the 
VEGF and DNA targets with each of the aptamer-functionalized particles (VA1, VA2, 
AA) for 8 h or, (3) serially incubated the aptamer-functionalized particles with each 
target. Results for incubation of the two VEGF aptamers (VA1 and VA2) with their 
labeled complementary sequence shown below in Figure 4.2.1.  
  
 
Figure 4.2.1: Surface densities of aptamer:DNA target duplexes of (a) VEGF aptamer 1 
(VA1) and (b) VEGF aptamer 2 (VA2) functionalized microspheres following incubation 
with only the FITC-labeled complementary target (VA1C*F or VA2C*F) (blue); 
incubated simultaneously with equivalent concentrations of the DNA target and VEGF 
(red); incubated first with VEGF and then with the complementary target (green), and 
incubated with the DNA target first and VEGF second (purple) under two annealing 
conditions: no anneal (NA), annealed prior (PA) to incubation with any target (DNA or 
VEGF). 
 
 The presence of VEGF prior, during, or following hybridization had little effect 
on duplex density values for in particles functionalized with VA1 as shown in Figure 




formation of the predicted self folded secondary structure in the aptamers. This result 
indicates that the primary DNA target may serve as a suitable trigger for VEGF release, 
but it is important to remember that it is unlikely that the immobilized aptamers are fully 
saturated with VEGF and/or DNA as the initial target. In particular, the fact that the 
coincubation showed similar duplex densities does indicate that the aptamer may possess 
a higher affinity for the DNA target than for VEGF. It should be noted that these 
conclusions cannot be drawn from this one study since VEGF is not labeled in these 
studies. 
 The results for VA2-functionalized particles shows a much different trend. 
Coincubation or serial incubation with VEGF severely hindered duplex formation for 
these particles. This result is especially true for the serial incubation of particles 
functionalized with VA2 where the complementary DNA target was first incubated with 
the aptamer-functionalized particles, resulting in a large decrease in the observed duplex 
density when compared to the duplex density when only the DNA target is incubated 
with the particles. This result could potentially arise from VEGF directly interfering with 
the formation of VA2:DNA target duplexes. Therefore, it is possible that this VA2 
aptamer possesses a higher affinity for its protein target and VEGF is capable of 
displacing this complementary DNA target. For the goals of this project, this combination 
of VEGF and DNA target may not allow for DNA-triggered release of bound VEGF. 
Future work would entail using a long DNA target with a higher affinity for the aptamer 
and provide better prospects as a displacement agent for VEGF. 
 Figure 4.2.2 shows the negative controls for the coincubation and serial 
incubation studies of the two VEGF aptamers: VA1 (a) and VA2 (b) shown in Figure 
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4.2.1. Samples were prepared as previously described, but a noncomplementary FAM-
labeled DNA sequence was used in place of the FAM-labeled DNA target. Negligible 
duplex densities were observed for all samples indicating that nonspecific binding did not 
occur due to the inclusion of VEGF in these studies. 
 
Figure 4.2.2: Surface densities of (a) VEGF aptamer 1 (VA1) and (b) VEGF aptamer 2 
(VA2) functionalized microspheres following incubation with only the FITC-labeled 
noncomplementary target (blue); incubated simultaneously with equivalent 
concentrations of the noncomplementary DNA target and VEGF (red), incubated first 
with VEGF and then with the noncomplementary target (green); and incubated first with 
noncomplementary DNA target and then with VEGF (purple) under two annealing 
conditions: no anneal (NA), annealed prior (PA) to incubation with the 
noncomplementary DNA target. 
 
 Figure 4.2.3 shows the qualitative results for hybridization of the AA-
functionalized particles when serially incubated with VEGF as a companion data set to 
the previous two figures. This study was included as a negative control to determine if 
VEGF presence would affect the hybridization efficiency of a particle functionalized with 
an aptamer that does not bind VEGF. It was observed that VEGF presence before or after 
incubation with the complementary target did not significantly affect duplex formation 






Figure 4.2.3: Surface densities of the aptamer:DNA target duplexes of ampicillin 
aptamer (AA) functionalized microspheres following incubation with FAM-labeled 
complementary DNA target only (AA:AAC*F); incubated first with the complementary 
target, and then with VEGF (AA:AAC*F+VEGF); and incubated first with VEGF and 
then the labeled complementary DNA target (AA+VEGF, +AAC*F) under two 
annealing conditions: no anneal (NA) and annealed prior (PA) to incubation with the 
complementary DNA target. 
 
 Figure 4.2.4 shows the qualitative results from a companion study to the one 
shown in Figure 4.2.1 using the unlabeled DNA target to evaluate the effects of the co-
presence of both primary targets on binding. For this study, VEGF was labeled as 
previously described using the Luminex labeling kit with the PE-streptavidin molecules 
to directly measure relative VEGF binding to the aptamer-functionalized particles. 
Additionally, for this study only  VA1-functionalized particles are analyzed since the 
success of displacing VEGF with DNA for the VA2-functionalized particles appears less 





Figure 4.2.4: Molecules of Equivalent Soluble Fluorophore (MESF) measured from 
adding phycoerythrin (PE) to VEGF incubated with VEGF aptamer 1 (VA1) 
functionalized microspheres, showing incubation with only the PE-labeled VEGF, 
aptamer functionalized microspheres incubated with the unlabeled DNA target first and 
VEGF second, incubated with VEGF first and the unlabeled DNA target second, and 
simultaneously incubated with equivalent concentrations of the unlabeled DNA target 
and VEGF when no anneal (NA) was applied to the microspheres (a) or annealed prior 
(PA) to the first incubation (b).  
 
 The inclusion of the complementary primary DNA target was shown to have little 
effect on VEGF binding to VA1-functionalized particles when no anneal has been 
performed on the suspensions. Based on previous studies, this could indicate that VA1 is 
capable of binding both of its primary targets simultaneously because neither target 
suffers a decrease in binding activity to the aptamer-functionalized particles when its 
counterpart is present. Thus, this choice in complementary DNA target maynot have a 
sufficient affinity advantage to serve as a displacement agent for VEGF bound to 
particle-immobilized aptamers. It may be possible that the inclusion of a synthetic 
oligonucleotide residue such as a locked nucleic acid (LNA) may be necessary to drive 
the release of the protein target from these immobilized aptamers. As shown previously 
by the Milam lab,
[1]




possesses a higher affinity for the A20 probe strand, forming more duplexes than its pure 
DNA counterparts. Moreover, LNA mixmers also served as effective displacement agents 
for pure DNA or for shorter or mismatched LNA targets. Thus, future experiments could 
explore LNA as a displacement agent for VEGF bound to aptamers for potential recovery 
of the aptamer's dual binding activity.  
4.3 Conclusions 
  Coincubation and serial incubation of the primary DNA and protein targets with 
aptamer-functionalized microspheres was investigated to elucidate the dual binding 
nature of the VEGF aptamer sequences. VA1 and VA2 showed distinct responses to these 
studies. VA1 seemed to nonpreferentially bind to either of its primary targets, potentially 
indicating that it is capable of binding VEGF, perhaps even to an aptamer hybridized to 
its DNA target. Single-stranded VA2, however, seemed to favor binding VEGF over its 
primary DNA target. Serial incubation of the DNA target followed by VEGF and 
coincubation of both targets, showed that VA2 bound less of its DNA target when VEGF 
was present and may indicate that it undergoes a conformational change to bind it protein 
target, blocking off the hybridization region of the aptamer sequence to our currently 
chosen DNA target.  
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REGENERATION OF APTAMER FUNCTIONALIZED 
COLLOIDAL PARTICLES THROUGH DNA MEDIATED 
INTERACTIONS 
INTRODUCTION 
 This chapter details using secondary hybridization events to trigger the release of 
DNA targets from aptamer:DNA target duplexes with the goal of fully recovering the 
binding activity of aptamers for either VEGF or DNA targets. Samples were prepared 
without any annealing step, as the objective  was to achieve full recovery of the aptamer's 
functionality without requiring the colloidal system to be exposed to further heat 
treatment, so that these interactions might be implemented in vivo in the future and to 
minimize the time required to reset the system for reuse in vitro. For this purpose two 
separate studies were performed. The first to evaluate secondary hybridization as a viable 
method to initiate the full release of aptamer:DNA target duplexes using a displacement 
agent (DA) and then achieve comparable levels of primary hybridization, following 
displacement of the original DNA target, while a final study evaluated the effects of 
DNA release on VEGF binding to the now unoccupied immobilized aptamers. An 
overview of the incubation series in shown in Figure 5.1.1, but the individual steps are 







5.1 Experimental Setup 
5.1.1 Displacement of Primary DNA Target via Hybridization of Primary DNA Target 
to the Displacement Agent 
 Primary hybridization was performed on two sets of samples as previously 
described
[1]
, using 100 µL  of 2 µM labeled (VA1C*F) or unlabeled (VA1C) 
complementary DNA. The incubation period of 8 hrs was chosen for these experiments. 
Following primary hybridization, three washed were performed at 9900g for 5 min, and  
the samples were resuspended in 500 µL of PBS/T, as previously described
[2]
. The 
samples were split into 100 µL aliquots. One of these aliquots was saved as a positive 
control to verify primary hybridization for the labeled complementary target. Four 100 
µL aliquots were then taken and incubated with the secondary unlabeled hybridization 
partner (DA) or a noncomplementary unlabeled sequence. Two samples were prepared 
for complementary secondary hybridization and one for the noncomplementary case.  
 
Figure 5.1.1: An Illustration showing how Aptamer:DNA target duplexes are incubated 
with (f) DNA displacement agent followed by removal of soluble duplexes followed by 
incubation with either (g) DNA target or (h) VEGF. In each case only one target species 
is labeled. Labeled DNA is conjugated with a FITC tag (*) on its 5' end. VEGF is labeled 
with phycoerythrin as illustrated in Scheme 3. 
 
5.1.2 Subsequent incubation of recycled aptamers to either VEGF or DNA target 
The secondary target is designed to hybridize to the primary target, using a four 




the release of hybridized  DNA and possibly a return to the original, unannealed state of 
the aptamer. One of the two aliquots from the complementary secondary hybridization 
were then washed and incubated with either the labeled primary DNA target or VEGF, in 
the case of the VA1C primary hybridization, as previously described. VEGF was labeled 
using the streptavidin associated PE label from the Luminex kit as previously described, 
and all samples were prepared for analysis using flow cytometry as previously described 
by the Milam lab.
[2] 
The particle suspensions were diluted to 1 mL using PBS/T following 
three washes (centrifugation at 9900xg for 3 min and resuspended in 100µL PBS/T) . The 
1 mL suspensions were analyzed on a Becton Dickinson LSR II flow cytometer (Becton 
Dickinson, San Jose, CA) using FACSDiva software (Beckton Dickinson). Calibration 
curves was generated using Quantum FITC-5 MESF standards (Bangs Laboratories, 
Fishers, IN)  or Quantum R-PE  MESF standard (Bangs Laboratories, Fishers, IN) and 
were diluted in the same buffer as the samples, allowing quantification of fluorescence 
intensity in molecules of equivalent soluble fluorophore (MESF). MESF units from the 
standards are used to convert the mean fluorescence of each sample to the mean number 
of targets associated to each particle. Suspensions of EDAC activated 1 µm PS beads, 
unactivated 1 µm PS beads, and DNA functionalized beads mixed with a 
noncomplementary target were included to verify that all hybridization corresponds to 
specific interactions between complementary DNA sequences. 
5.2 Results and Discussion 
5.2.1 Regeneration of Hybridization Activity using Secondary Hybridization 
  Ultimately, we hope to design a system capable of repeated binding and release 
events for targeted therapeutic delivery, using aptamers. Therefore, it is necessary to 
evaluate the ability of the aptamer to both of it primary targets repeated after release and 
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recovery of the aptamer. To accomplish this, we examined particles functionalized with 
VA1:VA1C*F duplexes and attempted to displace the DNA target from the duplex using 
a DNA displacement agent (DA). The DA sequence was designed to be fully 
complementary to the primary DNA targets, to allow all 20 bases present in the primary 
target hybridize to the displacement sequence and overcome the shorter in comparison to 
the 16 base-long hybridization segment between the target and its aptamer's sequence. 
The toehold region mentioned previously and shown underlined in Table 2.1.1 is a short 
segment of nucleotide, that a freely presented to the surrounding suspension and serve as 
a nucleation point for hybridization between the displacement agent and the primary 
DNA target, to promote displacement of the primary target. As described above, VA1-
functionalized particles were incubated with their FAM-labeled DNA target and allowed 
to hybridize. As a control, the hybridized aptamer-functionalized particles were incubated 
with a noncomplementary sequence to confirm that any DNA target release must be due 
to displacement by DA, and not due to simple duplex dissociation. Finally, the FAM-
labeled DNA target was reintroduced  to evaluate the ability of the VA1 aptamer to 
rebind its DNA target. As shown in Figure 5.2.1, incubation with the noncomplementary 
sequence does not affect the observed duplex densities; however, loss of the fluorescence 
associated with the DNA duplexes was introduced indicating that the reduction in duplex 
density must be due to successful displacement of the DNA target. The second incubation 
with the DNA target resulted in comparable duplex densities as aptamer-functionalized 
particles that had never been previously hybridized. Thus it was concluded that full 





5.2.1 Surface densities of aptamer:DNA target duplexes incubated under the following 
conditions: with the labeled DNA target (VA1C*F) alone, with the labeled DNA target 
followed by an unlabeled noncomplementary target (NC14), with the unlabeled 
complementary DNA target (VA1C) followed by the displacement agent (DA), and 
finally with the unlabeled complementary DNA target followed by the displacement 
agent and then incubated with the labeled complementary DNA target. 
  
 After verifying that recovery of the aptamer's hybridization efficiency was 
possible, it was necessary to evaluate that aptamer's ability to bind VEGF following 
displacement of the primary DNA target from the duplexes. Therefore, samples were 
prepared by hybridizing VA1-functionalized particles, displacing the primary target, and 
then incubating the now unoccupied aptamers with VEGF. Figure 5.2.2 shows these 
results as well as data for VEGF binding to particles that have not been annealed at any 
point during preparation. This data set was chosen for comparison because ideally the 
system would be capable of cyclic binding and release without further processing. Also 
included is a control in which VEGF was not incubated after the displacement agent to 
show that the displacement of the DNA target does not provide another source of 
nonspecific interactions for the PE labeling components. Figure 5.2.2 shows VEGF 
binding is greater to single-stranded aptamers prior to displacement events. Thus, 
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previously occupied VA1 aptamers were not able to fully recover binding activity to 
VEGF. 
 
Figure 5.2.2: Molecules of equivalent soluble fluorophore (MESF) measured from 
adding phycoerythrin (PE) to VA1-functionalized microspheres following incubation 
with VEGF only (VA1-VEGF); following incubation with the unlabeled complementary 
DNA target, then displacement agent (VA1:VA1C+DA, no VEGF) and finally 
incubated with VEGF (VA1:VA1C+DA, + VEGF). 
  
5.3 Conclusion 
  Recovery of the aptamer's dual binding nature was evaluated following 
displacement of the primary DNA target using a displacement agent designed to possess 
a higher affinity for the primary DNA target than the aptamer. Full recovery of the 
aptamer's ability to bind its DNA target after recovery of the unbound immobilized 
aptamer was achieved; however, only partial recovery of the aptamer's ability to bind 
VEGF was observed. Full recovery may be possible following the inclusion of a new 
annealing treatment, but our desire is to develop a system capable of repeated binding 
and release events in vivo; therefore, the effects of a separate anneal have not been tested 




5.4 Future Outlook 
In the future, it would be interesting to repeat this process for VA2; since it has 
shown signs of VEGF binding using the induced fit model; it may be capable of more 
complete recovery of its binding activity to VEGF. Additionally as previously discussed 
the inclusion of LNA residues in the DNA sequences, both aptamer and target, is of 
interest. LNA offers greater nuclease resistance and higher affinity for immobilized DNA 
probes,
[2]
 but complications arising from the more rigid structure, due to the restricted 
conformation of the sugar in the LNA backbone, would need to be assessed. 
Development of a PE label of known size (i.e. fluorescent polymeric subunits) and an 
appropriate standard should be a priority for future studies to directly monitor the binding 
activity of VEGF molecules to immobilized aptamer sequences. Finally, using a similar 
method as those outlined in this work to immobilize the blocking agent sequence, it 
would be possible to begin the development of a dual aptamer system for the delivery of 
multiple therapeutic molecules. 
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APPENDIX A  
Calculation of the DNA Concentration via UV-vis Spectral Analysis 
 As previously described, the DNA sequences were aliquoted and stored using 
Tris-EDTA (TE) buffer. FAM-labeled DNA sequences were stored in 10 µL aliquots at 
100 µM in pH 8.0 TE, and the unlabeled targets and aminated sequences were stored at 
the same concentrations in 20 µL aliquots using pH 7.4 TE buffer. Prior to incubation or 
coupling the samples were diluted to the appropriate concentrations as described in the 
previous chapter, depending on the experiment. To verify the concentration of the DNA 
solutions, UV-vis analysis and the Beer-Lambert law, shown below, were applied. IDT 
reports the individual extinction for all DNA sequences they synthesize.  
A=εlc                                                                           (1) 
 A corresponds to the measured absorbance of the DNA solution using UV-vis. 
The variables ε, l, and c correspond to the extinction coefficient, path length (the distance 
light travels through the material), and the concentration respectively. For our purposes 
the path length is equal to 1 cm. Samples of 150 µL (2 µM), diluted from 10 µL aliquots 
(100 µM), were analyzed and curves of wavelength (nm) vs. absorbance were generated. 
The characteristic peak associated with DNA occurs at 260 nm, and the measured value 
of absorbance at this concentration is used for concentration calculations. Figure A1 




Figure A.1: Plot of wavelength vs absorbance generated via UV-vis analysis of VEGF 
Aptamer 1 (VA1) DNA in solution, showing the characteristic peak at 260. 
 Additionally, a NanoVue Plus Spectrophotometer (GE Healthcare, Picataway, NJ) 
was used to verify the concentrations measured with the UV-vis spectrometer. All 
concentrations calculated with the two spectrometers agreed.  Table A1 lists the average 
calculated concentrations for each of the relevant sequences. 
Table A1: Calculated concentration of soluble DNA, using spectral analysis techniques. 


















APPENDIX B  
Calculation of the Radius of Gyration for PEG and VA1 Aptamer 
Sequence 
 Incorporation of 5 kDa PEG as a blocking agent lead to significant loss in 
hybridization of immobilized aptamer sequences, as shown in Chapter 2. To better 
understand the cause of this phenomenon the effective radius of gyration for both PEg 
and the VA1 aptamer sequence were calculated using the following equations. 




2                                                                             
 (2) 
Equation 1 is used to calculate the length of the extended aptamer sequence. Lp is the 
persistence length. For ssDNA Lp is equal to 4.6 nm. The variable l is a function of N, the 
number of bases in the sequence, and a, the effective nucleobase length (0.6 nm for 
ssDNA). Using these values the radius of gyration for the immobilized aptamer was 
calculated to be 9.22 nm in length. 
Equation 2 is uses the ideal chain model to calculate the length of the PEG polymer 
chain. C∞ is the Flory-Huggins characteristic ratio and is equal to 6.7 for PEG. The 
variables n and l correspond to the number of repeat units in the polymer chain and the 
length of the repeat unit respectively. For PEG l is equal to 1.1 nm. The PEG molecule 
utilized in this study was 5 kDA in size, corresponding to a chain of 173 repeat units. Rg 
was calculated to be 30.27 nm for 5 kDA PEG, meaning the elongated PEG strand was 
approximately three times the length of the aptamer sequence.  
